{"id":"W3009099064","doi":"10.1200/jco.19.03136","title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1154,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Hôpital Charles-Le Moyne","funders":"","keywords":"Pemetrexed; Medicine; Pembrolizumab; Lung cancer; Internal medicine; Hazard ratio; Placebo; Oncology; Progression-free survival; Response Evaluation Criteria in Solid Tumors; Surgery; Cancer; Progressive disease; Chemotherapy; Confidence interval; Pathology; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001486139,0.000292756,0.002894302,0.0002370935,0.00007703072,0.00003009373,0.0002241437,0.0003624385,0.001233588],"category_scores_gemma":[0.001549557,0.0001932932,0.0009759857,0.0007523168,0.0001774403,0.00009568721,0.00005525518,0.0007262219,0.000003560664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002986494,"about_ca_system_score_gemma":0.002985124,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007594969,"about_ca_topic_score_gemma":0.001146735,"domain_scores_codex":[0.9956742,0.0004178964,0.002791268,0.0004176742,0.0003252881,0.0003736897],"domain_scores_gemma":[0.9930788,0.003371416,0.002235746,0.000216568,0.0004679413,0.0006295579],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7553523,0.001739426,0.053486,0.0004940199,0.03524272,0.001624012,0.00251663,0.000986931,0.004237911,0.00000246827,0.03290837,0.1114092],"study_design_scores_gemma":[0.4306829,0.067333,0.1165393,0.0005425394,0.1105657,0.0003580475,0.002472692,0.1896623,0.002567722,0.00005325656,0.07796703,0.001255462],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816464,0.003319299,0.004234041,0.00881709,0.0004707316,0.001137499,0.0001293222,0.00002373774,0.0002219047],"genre_scores_gemma":[0.9803936,0.002354047,0.008489456,0.007211031,0.000796539,0.0000388597,0.00007362713,0.00004445355,0.0005983497],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3246694,"threshold_uncertainty_score":0.9996794,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1020767828221736,"score_gpt":0.432874076965801,"score_spread":0.3307972941436275,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}